Stephen J. Clarke

Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.

Use of the Internet by oncology patients: its effect on the doctor-patient relationship.

Pemetrexed: single-agent and combination phase I study overview.

Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy.

Thymidylate synthase inhibitors.

Population pharmacokinetics of weekly docetaxel in patients with advanced cancer.

Baseline nutritional assessment in advanced cancer patients receiving palliative chemotherapy.

Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.

Factors affecting cytochrome P-450 3A activity in cancer patients.

Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea.

A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.

Nutritional assessment in cancer: comparing the Mini-Nutritional Assessment (MNA) with the scored Patient-Generated Subjective Global Assessment (PGSGA).

Predicting the toxicity of weekly docetaxel in advanced cancer.

Advances in the adjuvant treatment of colorectal cancer.

Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients.

Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination.

Evaluation of nutritional and inflammatory status of advanced colorectal cancer patients and its correlation with survival.

Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial.

Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer.

Prognostic factors predictive of response and survival to a modified FOLFOX regimen: importance of an increased neutrophil count.

Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer.

Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.

Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing.

Potential regional differences for the tolerability profiles of fluoropyrimidines.

Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer.

Ethnic differences in drug metabolism and toxicity from chemotherapy.

Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials.

Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients--analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO.

A novel approach to investigate the subcellular distribution of nuclear receptors in vivo.

The alternatively spliced murine pregnane X receptor isoform, mPXR(delta171-211) exhibits a repressive action.

Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer.

Surface antigen profiling of colorectal cancer using antibody microarrays with fluorescence multiplexing.

Liver membrane proteome glycosylation changes in mice bearing an extra-hepatic tumor.

Clinicopathological correlates and prognostic significance of maspin expression in 450 patients after potentially curative resection of node-positive colonic cancer.

Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer.

Clinical trial information as a measure of quality cancer care.

Patient and oncologist estimates of survival in advanced cancer patients.

Taking less than prescribed: medication nonadherence and provider-patient relationships in lower-income, rural minority adults with hypertension.

High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy.

The development of multiple reaction monitoring assays for liver-derived plasma proteins.

Reporting clinical trial information: colorectal cancer trials at Sydney Cancer Centre.

Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine.

Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy.

Extrahepatic cancer suppresses nuclear receptor-regulated drug metabolism.

Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis.

Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a randomized controlled trial.

Medication adherence among rural, low-income hypertensive adults: a randomized trial of a multimedia community-based intervention.

Proteomic comparison of colorectal tumours and non-neoplastic mucosa from paired patient samples using iTRAQ mass spectrometry.

Clinical pharmacology of chemotherapy agents in older people with cancer.

An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs.

Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer.

Clinicopathological correlates and prognostic significance of glutathione S-transferase Pi expression in 468 patients after potentially curative resection of node-positive colonic cancer.

Src tyrosine kinase phosphorylation of nuclear receptor HNF4α correlates with isoform-specific loss of HNF4α in human colon cancer.